Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, December 2003, p. 3996-3997, Vol. 47, No. 12
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.12.3996-3997.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Susceptibilities of Fluoroquinolone-Resistant Haemophilus parainfluenzae Isolates from Japanese Patients with Respiratory Infections to Five Fluoroquinolones and Other Antimicrobial Agents

LETTER
Respiratory
tract infections remain a common cause of morbidity
and mortality
worldwide, and
Haemophilus spp. have been the
important
pathogens causing respiratory tract infections
(
2,
3).
Haemophilus
parainfluenzae is one of the pathogens that are
frequently
isolated from respiratory specimens, but the clinical
isolates are
usually neglected as indigenous bacteria of the
human respiratory
tract. However, recent case reports have indicated
that
H.
parainfluenzae might also be the causative organism
of certain
respiratory diseases, such as acute pneumonia
(
4,
7).
We have focused on
this bacterium by studying its prevalence
in patients, as well as the
antimicrobial susceptibilities of
the clinical isolates. Furthermore,
we identified some fluoroquinolone-resistant
strains of
H.
parainfluenzae (FRHP) in our collection.
Respiratory
specimens (e.g., sputum, pharyngeal swabs, and tonsillar swabs) were
collected from patients visiting the outpatient departments of 382
facilities all over Japan in 1998 to 2000. H.
influenzae (1,213 strains), H.
parainfluenzae (920 strains), H.
haemolyticus (232 strains), and H.
parahaemolyticus (111 strains) were isolated from the samples
collected in the 3 years. The MICs of some antimicrobial agents,
including levofloxacin, were determined for all of the strains by the
NCCLS standard broth microdilution method
(5). Ampicillin was
purchased from Wako Chemicals (Osaka, Japan), and all other
antimicrobial agents were kindly provided by the corresponding
manufacturers. We determined the fluoroquinolone-resistant strains of
Haemophilus spp. with the NCCLS breakpoint of levofloxacin,
>2 µg/ml
(6). The numbers of FRHP
isolates were 2 (2.4%), 16 (3.6%), and 13 (3.0%)
in 1998, 1999, and 2000, respectively, while only one or two
fluoroquinolone-resistant strains of the other Haemophilus
spp. were isolated. The distributions of drug MICs for H.
parainfluenzae, 20 fluoroquinolone-susceptible strains of
H. parainfluenzae (FSHP), and 30 FRHP isolates are
summarized in Table
1. All five fluoroquinolones exhibited excellent antimicrobial activity
against FSHP (MICs for 90% of the strains tested
[MIC90s],
0.015 to 0.06 µg/ml),
whereas each MIC90 of fluoroquinolones for FRHP was more
than 100-fold higher than that that for FSHP. Sitafloxacin exhibited a
clearly lower MIC90 (1 µg/ml) than did the other
fluoroquinolones. The susceptibilities of FRHP to other,
nonfluoroquinolone antimicrobial agents were similar to those of FSHP,
while two FRHP isolates exhibited lower susceptibilities to ampicillin
(MIC, >32 µg/ml).
To our knowledge, only a few
studies previously examined the
drug susceptibility of
H.
parainfluenzae. The recently reported
surveillance studies in
Europe (
2) and the United
States (
3)
indicated that
most
H. parainfluenzae isolates were susceptible
to
levofloxacin and other fluoroquinolones. This is the first
report
regarding clinical isolates of FRHP. It is conceivable
that the
fluoroquinolone resistance of FRHP described in this
report is caused
by genetic mutations in the
gyrA and/or the
parC gene
which likely occur in some other bacteria, such as
Streptococcus pneumoniae and
H. influenzae
(
1,
8). This bacterial
resistance
might be related to the selective pressure derived from the
prevalent
use of fluoroquinolones in Japan
(
8). Careful monitoring of
changes
in the drug susceptibility pattern of
H.
parainfluenzae, as
well as those of many other pathogens, is
important.
(This study was previously presented in part
[42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr.
C2-1994, p. 124].)

ACKNOWLEDGMENTS
We thank Shinsuke Matsuki, Suntory Co., Ltd.,
for assistance
with the collection of strains and Intetsu Kobayashi,
Mitsubishi
Kagaku Bio-Clinical Laboratories, for helpful assistance and
suggestions.

REFERENCES
1 - Biedenbach,
D. J., and R. N. Jones. 2000.
Fluoroquinolone-resistant Haemophilus influenzae: frequency of
occurrence and analysis of confirmed strains in the SENTRY
antimicrobial surveillance program (North and Latin America).Diagn. Microbiol. Infect. Dis.
36:255-259.[CrossRef][Medline]
2 - Felmingham,
D. 2000. Respiratory pathogens: assessing resistance
patterns in Europe and the potential role of grepafloxacin as treatment
of patients with infections caused by these organisms. J.
Antimicrob. Chemother. 45(Topic
T2):1-8.[Abstract]
3 - Hoban,
D. J., S. K. Bouchillon, J. L. Johnson,
G. G. Zhanel, D. L. Butler, L. A. Miller,
J. A. Poupard, and The Gemifloxacin Surveillance Study
Research Group. 2001. Comparative in vitro activity of
gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North
American surveillance study. Diagn. Microbiol. Infect.
Dis.
40:51-57.[CrossRef][Medline]
4 - Mitchell,
J. L., and S. L. Hill. 2000.
Immune response to Haemophilus parainfluenzae in patients with
chronic obstructive lung disease. Clin. Diagn. Lab.
Immunol.
7:25-30.[Abstract/Free Full Text]
5 - NCCLS.2001
. Methods for dilution antimicrobial susceptibility
tests for bacteria that grow aerobically, 5th ed. NCCLS document M7-A5.
NCCLS, Wayne,
Pa.
6 - NCCLS.2001
. Performance standards for antimicrobial
susceptibility testing, 11th informational supplement. NCCLS document M
100-S11. NCCLS, Wayne,
Pa.
7 - Pillai,
A., J. L. Mitchell, S. L. Hill, and R. A.
Stockley. 2000. A case of Haemophilus
parainfluenzae pneumonia. Thorax
55:623-624.[Abstract/Free Full Text]
8 - Yokota,
S., K. Sato, O. Kuwahara, S. Habadera, N. Tsukamoto, H. Ohuchi, H.
Akizawa, T. Himi, and N. Fujii. 2002.
Fluoroquinolone-resistant Streptococcus pneumoniae strains
occur frequently in elderly patients in Japan. Antimicrob.
Agents Chemother.
46:3311-3315.[Abstract/Free Full Text]
| | | | | |
Hiromu Takemura* Shigemi Terakubo Hiroyuki Yamamoto Jingoro Shimada Hideki Nakashima
Department of
Microbiology St. Marianna University School of Medicine 2-16-1
Sugao Miyamae-ku Kawasaki 216-8511,
Japan
Keiji Kanemitsu
Department of Molecular Diagnostics
Tohoku University Graduate School of Medicine
Sendai, Japan
|
| | | | | |
* Phone: 81 (44) 977-8111, Fax: 81 (44) 977-7818, E-mail: takeh{at}marianna-u.ac.jp> |
Antimicrobial Agents and Chemotherapy, December 2003, p. 3996-3997, Vol. 47, No. 12
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.12.3996-3997.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.